These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27794568)

  • 41. Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.
    Liu JF; Cannistra SA
    J Clin Oncol; 2014 May; 32(13):1287-9. PubMed ID: 24637996
    [No Abstract]   [Full Text] [Related]  

  • 42. [Not Available].
    Floquet A; Berton-Rigaud D; Ferron G; Freyer G; Hardy-Bessard AC; You B
    Bull Cancer; 2017 May; 104 Suppl 1():S24-S31. PubMed ID: 28625312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety of bevazicumab for the treatment of ovarian cancer.
    Bottoni C; Scambia G; Fagotti A; Petrillo M
    Expert Opin Drug Saf; 2018 Nov; 17(11):1107-1113. PubMed ID: 30286624
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical effect of mifepristone on patients with ovarian cancer in pregnancy.
    Shang L; Wang Y; Lyu Y
    Pak J Pharm Sci; 2019 Jan; 32(1(Special)):421-426. PubMed ID: 30852479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-angiogenic agents in ovarian cancer: dawn of a new era?
    Liu J; Matulonis UA
    Curr Oncol Rep; 2011 Dec; 13(6):450-8. PubMed ID: 21993845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-line therapy in ovarian cancer trials.
    Thigpen T; duBois A; McAlpine J; DiSaia P; Fujiwara K; Hoskins W; Kristensen G; Mannel R; Markman M; Pfisterer J; Quinn M; Reed N; Swart AM; Berek J; Colombo N; Freyer G; Gallardo D; Plante M; Poveda A; Rubinstein L; Bacon M; Kitchener H; Stuart GC;
    Int J Gynecol Cancer; 2011 May; 21(4):756-62. PubMed ID: 21543937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current First-line Therapy for Ovarian Cancer: A Comprehensive Review.
    Pierce SR; Clark LH
    Obstet Gynecol Surv; 2018 Nov; 73(11):650-657. PubMed ID: 30468240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Translational Theragnosis of Ovarian Cancer: where do we stand?
    Perrone MG; Luisi O; De Grassi A; Ferorelli S; Cormio G; Scilimati A
    Curr Med Chem; 2020; 27(34):5675-5715. PubMed ID: 31419925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
    Armstrong DK; Alvarez RD; Bakkum-Gamez JN; Barroilhet L; Behbakht K; Berchuck A; Berek JS; Chen LM; Cristea M; DeRosa M; ElNaggar AC; Gershenson DM; Gray HJ; Hakam A; Jain A; Johnston C; Leath CA; Liu J; Mahdi H; Matei D; McHale M; McLean K; O'Malley DM; Penson RT; Percac-Lima S; Ratner E; Remmenga SW; Sabbatini P; Werner TL; Zsiros E; Burns JL; Engh AM
    J Natl Compr Canc Netw; 2019 Aug; 17(8):896-909. PubMed ID: 31390583
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
    Markman M
    Gynecol Oncol; 2012 Jan; 124(1):171; author reply 171-2. PubMed ID: 21794901
    [No Abstract]   [Full Text] [Related]  

  • 51. Uncovering Metabolic Effects of Anti-angiogenic Therapy in Tumors by Induced Metabolic Bioluminescence Imaging.
    Indraccolo S; Walenta S; Mueller-Klieser W
    Methods Mol Biol; 2016; 1464():175-184. PubMed ID: 27858366
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet?
    Quesada S; Thomas QD; Colombo PE; Fiteni F
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.
    Nunes M; Henriques Abreu M; Bartosch C; Ricardo S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gastrointestinal perforations in a patient treated by Bevacizumab and chemotherapy: Is it an anaphylactic reaction?
    Lee WL; Chang WH; Wang PH
    Taiwan J Obstet Gynecol; 2020 Jul; 59(4):629-630. PubMed ID: 32653149
    [No Abstract]   [Full Text] [Related]  

  • 55. Bevacizumab: no comeback in early breast cancer?
    Bartsch R; Gnant M; Steger GG
    Lancet Oncol; 2015 Sep; 16(9):1001-1003. PubMed ID: 26272771
    [No Abstract]   [Full Text] [Related]  

  • 56. Chemotherapy-free, but not quite free chemotherapy.
    Schorge JO
    Lancet Oncol; 2019 Oct; 20(10):1335-1337. PubMed ID: 31474353
    [No Abstract]   [Full Text] [Related]  

  • 57. Ovarian cancer: state of the art and future directions.
    Awada A; Klastersky J
    Eur J Gynaecol Oncol; 2004; 25(6):673-6. PubMed ID: 15597841
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden-Baden Gynecologic Cancer Intergroup meeting.
    Eisenhauer EA
    Int J Gynecol Cancer; 2008; 18 Suppl 1():74-5. PubMed ID: 18336406
    [No Abstract]   [Full Text] [Related]  

  • 59. Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer.
    Nakai H; Matsumura N
    Ann Transl Med; 2023 Mar; 11(5):229. PubMed ID: 37007537
    [No Abstract]   [Full Text] [Related]  

  • 60. Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer.
    Hamilton G
    Transl Cancer Res; 2020 Apr; 9(4):2157-2160. PubMed ID: 35117573
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.